1 – 7 of 7
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2015
-
Mark
Treatment costs for advanced prostate cancer using luteinizing hormone-releasing hormone agonists: a solid biodegradable leuprorelin implant versus other formulations
(
- Contribution to journal › Article
- 2007
-
Mark
The predictive value of prostate cancer biomarkers depends on age and time to diagnosis: Towards a biologically-based screening strategy
(
- Contribution to journal › Article
- 2006
-
Mark
Tolerability, efficacy and pharmacokinetics of bicalutamide 300 mg, 450 mg or 600 mg as monotherapy for patients with locally advanced or metastatic prostate cancer, compared with castration
(
- Contribution to journal › Article
- 2001
-
Mark
Similar rates of exponential decrease in serum concentrations of free prostate-specific antigen (PSA), PSA complexed to alpha-1-antichymotrypsin, and human glandular kallikrein 2 (hK2) in prostate cancer patients treated with GnRH-analogues
(
- Contribution to journal › Article
- 2000
-
Mark
Discrimination of men with prostate cancer from those with benign disease by measurements of human glandular kallikrein 2 (HK2) in serum
(
- Contribution to journal › Article
- 1999
-
Mark
The prognostic value of different forms of prostate specific antigen and their ratios in patients with prostate cancer
(
- Contribution to journal › Article
- 1998
-
Mark
Metabolism of free and complexed prostate - specific antigen and their utility for diagnosis and prognosis of prostate cancer
1998)(
- Thesis › Doctoral thesis (compilation)